Effects of Early Exercise Rehabilitation in Severe Burns

August 10, 2020 updated by: Ulrike Van Daele, Universiteit Antwerpen

Pathophysiological Mechanisms and Early Exercise Rehabilitation Counter Measures of Hypermetabolism and Muscle Wasting in Severe Burns.

BACKGROUND:

Postburn changes in glucose and protein metabolism are at their peak during the acute phase of severe burns. The resulting metabolic derangements lead to substantial muscle wasting, insulin resistance, which ultimately hampers full recovery and reintegration into society.

PURPOSE:

This randomized controlled trial was initiated to investigate the effects of exercise-based rehabilitation on muscle wasting, insulin resistance, and quality of life during the acute phase of severe adult burns.

METHODS:

Severly burned adults (40-80%TBSA) will be recruited from one of China's largest burn centres.

Subjects allocated to the intervention group will undergo a 6-12 week long exercise program in addition to standard care rehabilitation. As part of the exercise program, participants will carry out progressive resistance and aerobic training, initiated as soon as medical safety and patient cooperation allow. Exercise type and dosage will be chosen according to patient status in terms of grafts, mobility, and strength.

The control group will receive standard care rehabilitation only, including passive, assisted, active range of motion exercise, functional exercise, and scar treatment.

The results of this translational research will provide insight into the effects and mechanisms of exercise on both a fundamental and clinical spectrum.

Study Overview

Status

Unknown

Conditions

Detailed Description

The added exercise intervention is initiated in line with the following readiness criteria, which were checked prior to each training session:

Criteria:

  • Cardiorespiratory stability:
  • Mean arterial pressure (MAP) 60 - 110 mmHg
  • fraction of inspired oxygen (FiO2) <60%
  • partial pressure of oxygen / fraction of inspired oxygen (PaO2/FiO2) >200
  • Respiratory rate <40 bpm
  • Positive end expiratory pressure (PEEP) <10 cmH2O
  • no high inotropic doses (Dopamine >10 mcg/kg/min or Nor/adrenaline <0,1 mcg/kg/min)
  • Temp. 36 - 38,5°C
  • Richmond Agitation Sedation Scale (RASS) -2 - +2
  • Medical Doctor clearance
  • Medical research council (MRC) score lower limbs ≥3

Accordingly, the post burn starting time differs per enrolled subject.

Exercises are administered as in-bed exercises or out-of-bed exercises, depending on whether subjects are able and allowed to engage in out-of-bed mobility.

Exercise intensity for resistance training is set at 60% peak force based on a weekly peak force measurement by hand-held dynamometry, or on a 3 RM in case of out of bed exercises. Aerobic exercise intensity is set at 50-75% peak Watts determined by a weekly cycle ergometer or treadmill ramp protocol.

Study Type

Interventional

Enrollment (Anticipated)

90

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Hubei
      • Wuhan, Hubei, China, 430060
        • Recruiting
        • Institute of Burns, Wuhan Third Hospital & Tongren Hospital of Wuhan University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 64 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • ≥40 - ≤70 %TBSA
  • Burn depth: 2nd deep / 3rd degree

Exclusion Criteria:

  • Electrical burn (except flash burns)
  • Associated injury: fracture lower limb
  • Diabetes Mellitus type 1
  • Central neurological/neuromuscular disorders (interfering with assessment/exercise)
  • Cognitive / psychological disorders (interfering with cooperation)
  • Cardiopulmonary disease (interfering with exercise safety)
  • Pregnancy
  • Palliative care

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Standard of Care

Standard of care treatment:

- including passive / assisted / active movements, stretching, functional exercise, scar treatment

Duration: 6-12 weeks

Standard of care rehabilitation
Experimental: Exercise

Standard of care + added exercises

Exercise type: resistance and aerobic exercise

Resistance Exercise: 3x / week (manual resistance, free weights, machines) Aerobic exercise: 2x / week (cycle ergometer, treadmill)

Duration: 6-12 weeks

Standard of care rehabilitation
Resistance and aerobic exercise in addition to standard of care rehabilitation

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in quadriceps muscle layer thickness (QMLT)
Time Frame: Baseline - 12 weeks

Method: B-mode ultrasound on the anterior aspect of the thigh. Technique: maximal and minimal pressure Location: measured at 1/2 and 2/3 of the distance between anterior superior iliac spine and the superior pole of the patella.

Analysis: An average of 3 trials will be recorded and analyzed using dedicated software

Baseline - 12 weeks
Change in rectus femoris cross sectional area (RF-CSA)
Time Frame: Baseline - 12 weeks

Method: B-mode ultrasound on the anterior aspect of the thigh. Technique: minimal pressure. Location: measured at the most proximal distance where the entire muscle belly is still visible on the ultrasound image.

Analysis: An average of 3 trials will be recorded and analyzed using dedicated software.

Baseline - 12 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in insulin resistance
Time Frame: Baseline and 12 weeks
Method: HOMA-2 calculated by fasting plasma glucose and insulin, analysed by Western Blot Chemiluminescence
Baseline and 12 weeks

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Interleukin-1
Time Frame: Baseline and 12 weeks
Western Blot Chemiluminescence
Baseline and 12 weeks
Change in Interleukin-6
Time Frame: Baseline and 12 weeks
Western Blot Chemiluminescence
Baseline and 12 weeks
Change in Tumor Necrosis Factor alpha (TNF-α)
Time Frame: Baseline and 12 weeks
Western Blot Chemiluminescence
Baseline and 12 weeks
Change in C-reactive protein
Time Frame: Baseline and 12 weeks
Western Blot Chemiluminescence
Baseline and 12 weeks
Change in Insulin like growth factor 1 (IGF-1)
Time Frame: Baseline and 12 weeks
Western Blot Chemiluminescence
Baseline and 12 weeks
Change in Glucagon
Time Frame: Baseline and 12 weeks
ELISA kits DGCG0, R&D Systems, Inc, USA
Baseline and 12 weeks
Change in Myostatin
Time Frame: Baseline and 12 weeks
ELISA kits DGDF80, R&D Systems, Inc, USA
Baseline and 12 weeks
Change in isometric peak force (knee extension)
Time Frame: Baseline and 12 weeks

Method: Hand-held dynamometry (Lafayette instrument Co. Europe, U.K.). Isometric peak fore is measured by a 'make' manoeuvre with a fixation band disallowing movement.

Test position: Supine with a fixation band fixed to the hospital bed. Analysis: Best of 3 trials

Baseline and 12 weeks
Change in isometric peak force (hip flexion)
Time Frame: Baseline and 12 weeks

Method: Hand-held dynamometry (Lafayette instrument Co. Europe, U.K.). Isometric peak fore is measured by a 'make' manoeuvre with a fixation band disallowing movement.

Test position: Supine with a fixation band fixed to the hospital bed. Analysis: Best of 3 trials

Baseline and 12 weeks
Change in isometric peak force (hip extension)
Time Frame: Baseline and 12 weeks

Method: Hand-held dynamometry (Lafayette instrument Co. Europe, U.K.). Isometric peak fore is measured by a 'make' manoeuvre with a fixation band disallowing movement.

Test position: Supine with a fixation band fixed to the hospital bed. Analysis: Best of 3 trials

Baseline and 12 weeks
Change in hand grip strength
Time Frame: Baseline and 12 weeks
Method: Baseline LITE hydraulic dynamometer Analysis: Best of 3 trials
Baseline and 12 weeks
Change in Burn Specific Health Scale-Brief (BSHS-B)
Time Frame: Baseline and 12 weeks

Burn-specific quality of life, measured by the Burn Specific Health Scale-Brief questionnaire (Mandarin Chinese version).

Total score 152 (0 worst score, 152 best score), consisting of 6 subdomains:

1) Body imagine (36 points) Simple abilities (36 points) Sexuality (24 points) Affect (32 points) Work (16 points) Interpersonal relationship (8 points)

Baseline and 12 weeks
Change in EQ-5D-5L
Time Frame: Baseline and 12 weeks

Overall quality of life, measured by EQ-5D-5L (Mandarin Chinese version) Total score: 25 points (0 worst score, 25 best score), consisting of 5 subdomains

  1. Mobility (5 points)
  2. Self-care (5 points)
  3. Usual activities (5 points)
  4. pain / discomfort (5 points)
  5. Anxiety / Depression (5 points) EQ overall health assessed on a Visual Analogue Scale, Total 0-100 (0 worst, 100 best score)
Baseline and 12 weeks
Number of adverse events
Time Frame: Baseline and 12 weeks
Recording of complications during exercise: Graft take, Wound infections, Medical, Cardio-respiratory safety
Baseline and 12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Ulrike Van Daele, Faculty of Medicine and Health Sciences, University of Antwerp

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 25, 2019

Primary Completion (Anticipated)

October 1, 2021

Study Completion (Anticipated)

October 1, 2021

Study Registration Dates

First Submitted

April 30, 2020

First Submitted That Met QC Criteria

April 30, 2020

First Posted (Actual)

May 4, 2020

Study Record Updates

Last Update Posted (Actual)

August 12, 2020

Last Update Submitted That Met QC Criteria

August 10, 2020

Last Verified

August 1, 2020

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 11B8619N

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Datasets will be made available upon request.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Burns

Clinical Trials on Standard of Care

3
Subscribe